Lung cancer treatment cost in Turkey

Lung cancer treatment cost in Turkey by diagnosis, stage, and treatment route

A dependable budget begins after tissue diagnosis identifies non-small-cell or small-cell lung cancer and staging establishes whether treatment is local, multimodal, or systemic. The estimate should show bronchoscopy or biopsy, pathology and molecular testing, thoracic surgery, radiotherapy planning, each medicine and cycle, breathing support, toxicity care, and surveillance as separate decisions.

How much does lung cancer treatment cost in Turkey?

A diagnostic and staging pathway in Turkey may be planned at TRY 94,000 to 282,000 (about USD 2,000 to 6,000). Selected early-stage surgery commonly requires TRY 470,000 to 1,175,000 (about USD 10,000 to 25,000), while a combined course using surgery, radiation, chemotherapy, targeted therapy, or immunotherapy may range from TRY 705,000 to 2,350,000 or more (about USD 15,000 to 50,000+). The drug identity and duration can move the final total far beyond a surgical package.

USD illustrations use about TRY 47 per USD, near the official indicative selling rate on 17 July 2026. Imported medicines and specialized radiation quotations may be linked to another currency, so confirm the billing currency, conversion date, named drug, dose, number of administrations, and quote validity.

Review cost scenarios Upload reports

Let Us Help You

Share the basics and the Virello team will guide you toward the next step.

Prefer email? Write to support@virellohealth.com.

Patient Name

Country

Phone Number

Describe The Current Medical Problem

Reviewed 2026-07-19

Clinical review: Virello Health Clinical Content Team · Editorial review: Virello Health Research Team

Billing context: TRY and USD

Histology changes the pathway

Non-small-cell and small-cell lung cancers are staged and treated differently; a quote issued before pathology is finalized is provisional.

Molecular results can dominate cost

Actionable alterations and PD-L1 expression may redirect care toward targeted or immune treatment with very different duration and monitoring.

Operability is more than scan stage

Pulmonary reserve, heart health, performance status, resection extent, and expected remaining lung function help determine whether surgery is reasonable.

Breathing problems need a local plan

Airway obstruction, pleural fluid, infection, clot, oxygen need, or sudden breathlessness may require urgent treatment before or during travel.

Cost at a glance

Planning scenarios for lung cancer treatment in Turkey

The scenarios separate routine and complex pathways. They are not fixed packages and should be replaced by a report-led hospital estimate before travel.

Estimated lung cancer treatment cost scenarios in Turkey
Scenario	TRY	USD	Patient and treatment context	Planning scope
Diagnosis and stage clarification	TRY 94,000 - 282,000	USD 2,000 - 6,000	A lung mass or confirmed cancer requiring pathology review, bronchoscopy or image-guided biopsy, PET-CT or stage imaging, lung-function assessment, and actionable biomarker work.	The quotation should name the biopsy method, anesthesia, pathology, molecular panel, PD-L1 test, imaging, cardiopulmonary assessment, and the review that converts results into a plan.
Resectable surgery-led care	TRY 470,000 - 1,175,000	USD 10,000 - 25,000	Selected localized non-small-cell cancer treated with segmentectomy, lobectomy, or another defined resection and systematic node evaluation.	Include open or minimally invasive approach, surgeon, anesthesia, theatre, pathology, chest-drain care, ward or ICU allowance, respiratory therapy, and early follow-up.
Multimodal or advanced pathway	TRY 705,000 - 2,350,000+	USD 15,000 - 50,000+	Locally advanced, small-cell, metastatic, recurrent, or biomarker-directed disease needing radiation and multiple systemic-treatment phases.	Price by treatment phase and time horizon; targeted medicines, checkpoint inhibitors, prolonged maintenance, complications, and repeat scans prevent a guaranteed lifetime total.

Usually included

Check the clinical package scope

Named thoracic procedure

The exact biopsy, bronchoscopy, segmentectomy, lobectomy, pneumonectomy, or node procedure stated in the clinical plan.

Confirm whether robotic, thoracoscopic, or open access and conversion are priced.

Routine admission scope

Surgeon, anesthesia, operating room, standard consumables, specified room, routine chest imaging, medicines, and chest-drain management.

Ask for daily ward, high-dependency, and ICU rates beyond the allowance.

Standard surgical pathology

Tumor type, grade where applicable, margins, nodes, pathologic stage, and routine reporting on removed tissue.

Molecular profiling and outside slide review may be excluded.

Early recovery review

Wound assessment, drain or suture plan, pathology discussion, breathing exercises, and referral to the next oncology phase.

Obtain a safe-to-fly decision rather than using a fixed travel date.

Confirm separately

Charges that may sit outside the range

Advanced diagnosis and biomarkers

PET-CT, brain MRI, bronchoscopy technologies, repeat biopsy, broad sequencing, PD-L1, and liquid biopsy unless listed.

Ask which results are essential before any irreversible treatment.

Radiotherapy course

Simulation, contouring, planning, physics checks, image guidance, motion control, every fraction, and weekly review.

A per-session price cannot describe a complete prescribed course.

Systemic treatment

Chemotherapy, targeted therapy, immunotherapy, maintenance medicines, anti-nausea drugs, growth factors, and infusion services.

Require generic name, brand, dose, schedule, and planned assessment point.

Unplanned respiratory care

Prolonged air leak, pneumonia, pleural drainage, oxygen, embolism care, readmission, airway stent, or ICU treatment.

Maintain an emergency reserve and clarify package boundaries.

Candidate context

Who may be considered and what else may be discussed

The treatment decision uses pathology, TNM stage, non-small-cell subtype or small-cell classification, molecular alterations, PD-L1, tumor location, nodal involvement, symptoms, brain or distant spread, lung function, heart health, performance status, smoking history, previous treatment, and patient goals. A thoracic multidisciplinary team should decide whether the aim is cure, durable control, or symptom relief and whether surgery, radiation, systemic therapy, or a sequence is most appropriate.

Information that shapes suitability

Tissue and subtype

Adequate biopsy material should confirm malignancy and histology while preserving enough tissue for tests that may change first-line treatment.

Accurate stage

Chest and body imaging, brain assessment when indicated, and invasive mediastinal staging in selected cases distinguish local, nodal, and metastatic disease.

Cardiopulmonary fitness

Spirometry, diffusion capacity, exercise assessment, cardiac review, frailty, nutrition, and functional status shape surgery and radiation safety.

Urgent clinical issues

Major coughing of blood, severe breathlessness, superior vena cava obstruction, spinal symptoms, infection, or brain symptoms require prompt local assessment.

Alternatives or sequencing questions

Stereotactic radiation for selected early disease

Patients who cannot undergo surgery may be considered for highly focused radiation after diagnostic, staging, and motion-management review.

Definitive chemoradiation

Selected locally advanced disease may use concurrent or sequential systemic treatment and radiation, sometimes followed by maintenance therapy.

Biomarker-directed systemic therapy

A confirmed actionable alteration can support a matched medicine, with response scans, resistance planning, and monitoring for organ-specific toxicity.

Palliative and symptom-directed care

Radiation, drainage, airway procedures, medicines, oxygen, pain care, and supportive oncology can improve symptoms alongside or instead of tumor-directed treatment.

Procedure variations

Why the named procedure does not have one price

Technique, device, medicine, treatment extent, and prior care can change both the clinical plan and the estimate.

Segmentectomy or wedge resection

Removes less lung than a lobectomy for carefully selected tumors or limited reserve.

Ask about margins and lymph-node assessment, not incision size alone.

Lobectomy with nodal evaluation

Removes one lobe and samples or dissects regional nodes using open, VATS, or robotic access.

Approach choice should reflect anatomy and team experience.

Definitive radiation pathway

May use stereotactic treatment or a longer conventionally fractionated course according to stage and nearby organs.

Confirm total dose, fractions, motion control, and interruption policy.

Systemic-first pathway

Chemotherapy, targeted therapy, or immunotherapy may precede local care or remain the main treatment for advanced disease.

Build the budget to the first response review and then model likely continuation.

City comparison

Cost and capability by city in Turkey

Only cities with evidence for the procedure should appear here. A city range does not prove that every hospital in that city can manage the same case complexity.

Estimated lung cancer treatment costs and planning context by city in Turkey
City	Local range	USD range	Capability context	Stay planning
Istanbul	TRY 470,000 - 2,820,000+	USD 10,000 - 60,000+	Broad access to thoracic surgery, interventional pulmonology, molecular pathology, radiation, and systemic oncology.	Premium hospitals and prolonged medicine courses can outweigh flight savings.
Ankara	TRY 423,000 - 2,350,000+	USD 9,000 - 50,000+	Major university, public, and private thoracic oncology programs are available.	Confirm international self-pay access and turnaround for the required panel.
Izmir	TRY 399,500 - 2,115,000+	USD 8,500 - 45,000+	Selected tertiary centers provide integrated surgery and oncology services.	Verify interventional pulmonology and radiation technique at hospital level.
Antalya	TRY 423,000 - 2,256,000+	USD 9,000 - 48,000+	International coordination is common, while complex thoracic depth differs by facility.	Separate hotel-inclusive offers from drugs, pathology, and emergency care.
Bursa	TRY 376,000 - 1,880,000+	USD 8,000 - 40,000+	Qualified tertiary programs may offer value for standard surgery and multimodal care.	Check ICU, bronchoscopy, molecular, and radiation availability together.
Kocaeli and Gebze	TRY 399,500 - 1,974,000+	USD 8,500 - 42,000+	Marmara centers can provide access near Istanbul transport corridors.	Daily radiation travel and emergency route need practical mapping.
Adana	TRY 352,500 - 1,786,000+	USD 7,500 - 38,000+	Regional academic and tertiary services may support selected lung pathways.	Confirm the named thoracic surgeon and medicine stock before arrival.
Konya	TRY 329,000 - 1,645,000+	USD 7,000 - 35,000+	Potential value exists for clearly defined standard care at documented centers.	Avoid splitting pathology, surgery, and oncology without one case lead.
Kayseri	TRY 329,000 - 1,645,000+	USD 7,000 - 35,000+	Selected tertiary programs can assess surgery and systemic treatment.	Plan flight fitness and rapid access for fever or breathlessness.
Gaziantep	TRY 305,500 - 1,504,000+	USD 6,500 - 32,000+	Advanced capabilities and medicine access require direct verification.	Choose only after receiving the complete staged sequence in writing.

Estimate variables

What can change the final hospital cost

Histology and stage

Early non-small-cell, locally advanced disease, small-cell cancer, and metastatic cancer need materially different treatment plans.

The clinician should state the stage system and treatment intent.

Biomarker profile

Actionable molecular alterations and immune markers determine whether prolonged targeted or checkpoint treatment may be appropriate.

Budget after the required assay and sample adequacy are known.

Operation and postoperative course

Resection extent, access, nodal work, adhesions, lung reserve, air leak, and ICU use influence cost and stay.

Ask how conversion and prolonged drainage are billed.

Radiation complexity

Stereotactic, definitive thoracic, brain, bone, or other palliative courses use different planning, fractions, and technology.

Price the prescribed course from simulation to completion.

Medicine and duration

Generic cytotoxic drugs, oral targeted agents, immune combinations, maintenance, and body-size dosing produce a very wide range.

Model the initial phase and response-dependent continuation separately.

Medical cost breakdown

Before admission, in hospital, and after discharge

Diagnostics and preparation

Biopsy and pathology

Bronchoscopy, EBUS, CT-guided biopsy, surgery, cytology, immunohistochemistry, and outside review according to lesion location.

Sample adequacy can prevent a second invasive procedure.

Stage imaging

Contrast CT, PET-CT, brain MRI, and targeted assessment of suspicious sites when clinically indicated.

Send DICOM images for review, not screenshots.

Molecular and immune tests

Focused or broad tumor profiling, PD-L1, and selected blood-based assays with known limitations.

Ask which laboratory, genes, method, and turnaround apply.

Fitness testing

Pulmonary function, cardiac assessment, laboratory work, nutrition, and exercise or perfusion studies for selected surgery candidates.

Testing should answer a clinical decision, not inflate a package.

Admission and treatment

Thoracic operation

Surgical team, anesthesia, theatre, stapling and energy devices, pathology, chest drainage, ward, and stated critical-care allowance.

Clarify blood, complications, and extra-day rates.

Infusion or oral treatment

Medicine acquisition, pharmacy preparation, nursing, laboratory checks, supportive care, and treatment review.

Oral therapy still requires monitoring and refill planning.

Radiation delivery

Consultation, immobilization, simulation, contouring, planning, quality assurance, image guidance, fractions, and on-treatment review.

Ask what happens if the machine is unavailable.

Recovery and follow-up

Respiratory rehabilitation

Breathing exercises, walking progression, secretion clearance, oxygen reassessment, nutrition, and smoking cessation support.

Arrange continuation after returning home.

Toxicity surveillance

Blood counts, organ tests, infection review, immune-toxicity checks, and management of radiation inflammation or swallowing pain.

Know which symptoms require emergency care.

Response and recurrence imaging

Scheduled CT, PET-CT, or brain imaging linked to treatment phase and symptoms.

Use the same comparison studies and transfer DICOM files.

Complete journey budget

Plan beyond the hospital invoice

Patient and attendant costs should be modeled separately from the medical estimate, with flexible dates and a contingency reserve.

Duration-based accommodation

Surgery, definitive radiation, and systemic treatment require very different stays and may be split into multiple trips.

Price housing near the actual treatment site.

Companion and mobility needs

Transport, oxygen logistics where approved, meals, translation, and help during fatigue or breathlessness.

Airlines may require medical clearance for oxygen.

Delay and emergency reserve

Repeat biopsy, low blood counts, infection, air leak, changed flights, extra scans, or unplanned admission can extend the journey.

Do not rely on a non-refundable return date.

Country access

Rules and practical requirements to verify

Visa, donor, fertility, medicine, licensing, and treatment-access requirements can change. Confirm current rules with the relevant authority and treating hospital.

Verify international-patient authorization

Check the current Turkish Ministry of Health list for the facility and confirm that the named thoracic and oncology services are provided at that location.

Confirm radiation department scope

Ask about the radiation oncologist, physicist, machine, motion management, quality assurance, fraction schedule, and backup arrangements.

Validate medicine access

Approval and availability can differ by indication. Obtain generic name, brand, dose, procurement time, storage, and self-pay conditions in writing.

Plan oxygen and flight clearance

Airline, airport, cylinder, concentrator, and battery rules vary; the treating respiratory team should assess travel fitness.

Use official entry information

Check the Turkish government e-Visa service or the appropriate mission for nationality-specific requirements rather than relying on an agent screenshot.

Hospital selection

Compare capability before package price

Thoracic multidisciplinary team

Thoracic surgeon, pulmonologist, medical oncologist, radiation oncologist, radiologist, pathologist, nuclear medicine, and supportive care.

Ask when and how the case is reviewed.

Diagnostic capability

Bronchoscopy and EBUS, image-guided biopsy, pathology, molecular testing, PET-CT, brain MRI, and pulmonary function.

Confirm turnaround and repeat-biopsy policy.

Surgery and rescue services

Experienced thoracic anesthesia, VATS or robotics as offered, ICU, chest medicine, interventional radiology, infection, and thrombosis care.

Technology does not substitute for team volume and rescue systems.

Integrated oncology delivery

Modern radiation, pharmacy, infusion, targeted and immune treatment, toxicity triage, nutrition, pain, and palliative care.

One accountable coordinator should connect every phase.

Meaningful outcomes

Stage-specific mortality, complications, margin, node quality, treatment completion, readmission, and follow-up definitions.

Reject a universal success or cure claim.

Treating team

Specialists and support that may matter

Thoracic surgeon

Assesses resectability, operation extent, access, nodes, lung preservation, complication risk, and postoperative pathology.

Pulmonologist and interventional team

Obtain tissue, stage mediastinal nodes, assess breathing, manage airways and pleural problems, and support recovery.

Medical oncologist

Selects cytotoxic, targeted, or immune treatment according to histology, stage, biomarkers, health, response, and toxicity.

Radiation oncologist

Plans stereotactic, definitive, postoperative, brain, bone, or symptom-directed radiation while protecting critical organs.

Thoracic pathologist and molecular laboratory

Confirm subtype, preserve tissue, report clinically relevant markers, and reconcile discordant results before treatment.

Treatment timeline

From report review to return-home follow-up

Remote triage

Send pathology, imaging in DICOM, molecular reports, symptoms, breathing status, medicines, prior cancer care, and functional limitations.

Diagnosis and staging completion

Review tissue adequacy, perform only decision-changing biopsy or imaging, assess cardiopulmonary fitness, and finalize stage.

Multidisciplinary recommendation

The team records treatment intent, alternatives, sequence, expected duration, transfer-home options, and cost phases.

Initial treatment

Proceed with surgery, radiation, systemic treatment, or symptom stabilization according to the agreed pathway.

Response or pathology review

Postoperative findings or interval scans determine whether the next phase continues, changes, or stops.

Home handover

Transfer diagnosis, stage, biomarkers, operation, pathology, drugs, radiation, toxicities, oxygen needs, emergency signs, and surveillance schedule.

Risks and edge cases

Events that can change the plan, stay, or cost

Insufficient biopsy tissue

Diagnosis may be established but the sample may not support required molecular tests.

Discuss repeat tissue biopsy versus a validated blood assay and its limits.

Prolonged air leak or pneumonia

Chest drainage, antibiotics, bronchoscopy, oxygen, or an extended admission can delay flight and adjuvant care.

Request daily rates and safe-to-fly criteria.

Brain metastasis or neurologic change

New weakness, seizure, confusion, severe headache, or balance change may require urgent imaging and local treatment.

Do not travel before urgent assessment.

Immune or targeted-treatment toxicity

Lung inflammation, diarrhea, liver or endocrine changes, skin effects, rhythm issues, or interactions can require rapid evaluation.

Carry a treatment card and emergency contacts.

Airway or vessel emergency

Major bleeding, stridor, severe breathlessness, facial swelling, chest pain, or low oxygen can be life-threatening.

Use immediate local emergency services instead of waiting for overseas transfer.

Destination comparison

Compare India, Turkey, and Thailand for this procedure

The most suitable destination depends on the individual case, required team, treatment availability, travel route, legal eligibility, budget, and continuity after returning home.

Procedure planning comparison across India, Turkey, and Thailand
Decision factor	India	Turkey	Thailand	How to use this
Thoracic oncology concentration	Large volumes across major metros with variable regional depth.	Integrated expertise is strongest in Istanbul, Ankara, and selected tertiary hubs.	Advanced private care is concentrated mainly in Bangkok.	Compare named teams, staging tools, and rescue capability.
Molecular and medicine budget	Testing and biosimilar options may reduce some costs, but access varies.	Imported targeted and immune medicines may be quoted in TRY, EUR, or USD.	Private medicine pricing can be high for prolonged originator therapy.	Match the exact marker, medicine, dose, and treatment horizon.
Radiation logistics	Wide machine availability with center-specific motion and stereotactic capability.	Modern platforms exist at major programs, with regional variation.	High-end platforms are available in leading hospitals.	Ask about prescribed fractions, quality assurance, and interruption backup.
Travel practicality	Longer travel for some European and regional patients.	Convenient geography for Europe, Central Asia, Middle East, and North Africa.	Long-distance return may complicate breathlessness or repeated treatment.	Flight fitness and home emergency access matter more than airfare alone.

Decision guidance

When Turkey may fit and when to keep comparing

Turkey may be suitable when

A verified center confirms pathology, stage, molecular testing, cardiopulmonary fitness, the complete sequence, and a workable home-care handover.

Continue comparing when

The estimate offers surgery without nodal or pathology scope, recommends medicine before biomarkers, or quotes radiation by one session.

Obtain another review when

Teams disagree about resectability, biopsy adequacy, stage, operation extent, chemoradiation, or a high-cost targeted or immune treatment.

Stay with urgent local care when

There is major bleeding, rapidly worsening breathing, low oxygen, chest pain, fever during treatment, seizure, confusion, or new weakness.

Reports for review

Prepare a case file before requesting estimates

Provide a dated clinical record that allows the Turkey team to verify tissue diagnosis, stage, molecular findings, cardiopulmonary reserve, prior treatment, symptoms, and travel safety. Original pathology and DICOM imaging are more useful than a short translated summary alone.

Upload medical reports

Pathology and molecular evidence

Biopsy and cytology reports

Include specimen site, method, date, histology, immunostains, and diagnostic limitations.

Slides, blocks, and tissue availability

State what material remains and whether release and international transport are permitted.

Molecular and PD-L1 results

Send complete laboratory reports with method, sample, genes, variants, score, and date.

Prior pathology review

Include any disagreement and the evidence used to resolve it.

Stage and fitness

Chest and body imaging

Share contrast CT and PET-CT DICOM studies plus reports and dates.

Brain and nodal assessment

Add brain imaging, EBUS, mediastinoscopy, or node-biopsy information when performed.

Pulmonary and cardiac tests

Provide spirometry, diffusion, oxygen, exercise, ECG, echo, and relevant specialist notes.

Symptoms and function

Describe breathlessness, cough, bleeding, pain, weight loss, walking ability, and support needs.

Treatment and travel safety

Cancer treatment chronology

List operations, radiation fields and doses, drugs and doses, dates, response, and toxicities.

Current medicines and illnesses

Include anticoagulants, steroids, oxygen, allergies, smoking, infection, and organ disease.

Recent laboratory results

Send blood count, kidney, liver, electrolytes, coagulation, and relevant cultures.

Travel and home contacts

Add nationality, companion, airline oxygen needs, home oncologist, and intended travel window.

Common questions

Questions about cost, travel, and follow-up

Is lung cancer surgery always possible?

No. Histology, stage, tumor position, nodes, distant spread, remaining lung function, heart health, and general fitness determine whether an operation is appropriate.

Does the price include molecular testing?

Only when the quotation names the panel, laboratory, sample, genes or markers, method, pathology review, turnaround, and repeat-testing policy.

What is the difference between NSCLC and small-cell treatment?

They have different staging and treatment patterns. Non-small-cell disease may use surgery, radiation, targeted therapy, immunotherapy, or chemotherapy, while small-cell care more often centers on systemic treatment and radiation.

Can I receive chemotherapy or immunotherapy at home?

Sometimes, if the home oncology service accepts the prescription and can obtain the medicine, monitor toxicity, perform response imaging, and communicate with the overseas team.

How is radiation priced?

Ask for consultation, simulation, planning, motion management, quality assurance, image guidance, the total prescribed fractions, treatment reviews, and a policy for interrupted sessions.

How long should I stay after lung surgery?

Stay depends on recovery, chest-drain removal, oxygen level, pain control, mobility, pathology timing, complication risk, and clinician-confirmed flight fitness rather than a package date.

Does robotic surgery improve every outcome?

Robotic access may support minimally invasive surgery in suitable cases, but cancer clearance, node evaluation, team experience, complication rescue, and proper candidate selection remain central.

What if my biopsy does not have enough tissue?

The team may review remaining blocks, use another specimen, consider repeat biopsy, or use a blood-based assay in selected situations while explaining its limitations.

Why can immunotherapy make the total unpredictable?

Cost depends on eligibility, medicine, dose, interval, response, duration, immune side effects, scans, and whether treatment is held, stopped, or combined with chemotherapy.

When should I seek emergency care?

Major coughing of blood, severe or sudden breathlessness, chest pain, low oxygen, fever during treatment, confusion, seizure, or new weakness needs urgent local assessment.

Review and sources

How this guide was prepared

Planning bands separate diagnosis, resectable surgery, and multimodal disease instead of converting a single advertised package. Current Turkey market signals were normalized near TRY 47 per USD and tested against tissue acquisition, stage imaging, molecular work, cardiopulmonary assessment, surgery, radiation, named medicines, toxicity care, and return-home continuity. Clinical structure follows current NCI lung-cancer and biomarker material; provider and radiation checks use Turkish Ministry of Health resources. The ranges are budgeting tools, not tariffs or treatment recommendations.

This page is educational and does not establish diagnosis, stage, operability, medicine eligibility, prognosis, travel fitness, or an individual price. Decisions require tissue, appropriate staging, cardiopulmonary assessment, multidisciplinary review, and a written time-limited quotation. Major bleeding, rapidly worsening breathing, low oxygen, chest pain, fever during treatment, seizure, confusion, or new weakness requires urgent local care.

Related planning